This paper is in the following e-collection/theme issue:

Reviews on Usage or other Formative Evaluation Metrics (59) Cost-Effectiveness and Economics (355) Implantable Drug Delivery Systems, Ingestible Sensors and Digital Pills (16) Gastroenterology and Hepatology (127)

Published on in Vol 5, No 1 (2021): January

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/13888, first published .
Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment

Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment

Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment

Authors of this article:

Mattias Neyt1 Author Orcid Image ;   Annick Christiaens2 Author Orcid Image ;   Marina Aloi3 Author Orcid Image ;   Lissy de Ridder4 Author Orcid Image ;   Nicholas M Croft5 Author Orcid Image ;   Sibylle Koletzko6, 7 Author Orcid Image ;   Arie Levine8 Author Orcid Image ;   Dan Turner9 Author Orcid Image ;   Richard K Russell10 Author Orcid Image ;   Frank M Ruemmele11, 12 Author Orcid Image ;   Gigi Veereman13 Author Orcid Image
Article Authors Cited by (1) Tweetations (3) Metrics

Journals

  1. Duquerois A, Martinez-Vinson C, Loppinet T, Restier L, Poinsot P, Portefaix A, Heissat S, Peretti N, Caron N, Duclaux-Loras R. A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy. Clinics and Research in Hepatology and Gastroenterology 2025;49(8):102680 View